Fiala Katherine H, Whetteckey Jacqueline, Manyam Bala V
Department of Neurology, Texas A and M University System, Health Science Center College of Medicine, 2401 South 31st Street, Temple, TX 76508, USA.
Parkinsonism Relat Disord. 2003 Aug;9(6):321-7. doi: 10.1016/s1353-8020(03)00040-3.
Levodopa is the major drug used in the treatment of patients with Parkinson's disease. However, levodopa continues to be 'contra-indicated' for patients with Parkinson's disease associated with malignant melanoma. Case reports have suggested that levodopa has a causal relationship with malignant melanoma due to their shared dopamine biochemical pathway. Clinical characteristics of 54 patients with both Parkinson's disease and melanoma were analyzed (43 cases from the literature and 11 from our institution). The results suggest that the occurrence of both Parkinson's disease and melanoma in these patients is coincidental rather than causal. It did not appear that the Parkinson's disease patients on levodopa therapy were predisposed to melanoma, nor did levodopa therapy appear to exaggerate melanoma if it were previously present.
左旋多巴是治疗帕金森病患者的主要药物。然而，左旋多巴对于患有与恶性黑色素瘤相关的帕金森病患者仍为“禁忌”。病例报告表明，由于左旋多巴和恶性黑色素瘤共享多巴胺生化途径，二者之间存在因果关系。分析了54例同时患有帕金森病和黑色素瘤患者的临床特征（43例来自文献，11例来自我们机构）。结果表明，这些患者中帕金森病和黑色素瘤的发生是巧合而非因果关系。接受左旋多巴治疗的帕金森病患者似乎没有患黑色素瘤的倾向，而且如果先前已存在黑色素瘤，左旋多巴治疗似乎也不会使其恶化。
